Literature DB >> 6651594

A prognostic factor study of disease-free interval and survival following enucleation for uveal melanoma.

J M Seddon, D M Albert, P T Lavin, N Robinson.   

Abstract

Prognostic indicators of uveal melanoma disease-free interval and survival following enucleation were evaluated for 267 patients. The median follow-up time was 17 years. Analysis involved Kaplan-Meier survival curves based on time to tumor-related deaths and multivariate proportional hazards analysis, which provides an estimate of the "force of mortality." Prognostic indicators considered included demographic, clinical, and histopathological factors. Cell type was classified according to the number of epithelioid cells present per high-power field (HPF) on light microscopy. Various classifications of size of the tumor were compared for prognostic value. The five leading predictors of survival in order of importance were as follows: (1) number of epithelioid cells per HPF, (2) largest dimension of the tumor, (3) location of the anterior margin of the tumor, (4) invasion to the line of transection, and (5) degree of pigmentation. Risk categories for survival were constructed based on the three leading prognostic factors.

Entities:  

Mesh:

Year:  1983        PMID: 6651594     DOI: 10.1001/archopht.1983.01040020896012

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  43 in total

1.  GDF-15: a novel serum marker for metastases in uveal melanoma patients.

Authors:  Daniela Suesskind; Andreas Schatz; Sven Schnichels; Sarah E Coupland; Sarah L Lake; Bernd Wissinger; Karl U Bartz-Schmidt; Sigrid Henke-Fahle
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-09-01       Impact factor: 3.117

2.  Cytomorphometry of uveal melanomas: fine needle aspiration biopsy versus standard histology.

Authors:  D H Char; S M Kroll; A Stoloff; J B Crawford; T R Miller; E L Howes; P Crawford
Journal:  Trans Am Ophthalmol Soc       Date:  1989

3.  Uveal melanoma management.

Authors:  D H Char; E S Gragoudas; T L Phillips
Journal:  Br J Ophthalmol       Date:  1989-06       Impact factor: 4.638

4.  Proton therapy for uveal melanomas and other eye lesions.

Authors:  J E Munzenrider
Journal:  Strahlenther Onkol       Date:  1999-06       Impact factor: 3.621

5.  Expression of VLA-2, VLA-3, and alpha(v) integrin receptors in uveal melanoma: association with microvascular architecture of the tumour and prognostic value.

Authors:  G Anastassiou; H Schilling; S Djakovic; N Bornfeld
Journal:  Br J Ophthalmol       Date:  2000-08       Impact factor: 4.638

6.  Modelling uveal melanoma.

Authors:  A J Foss; I A Cree; P J Dolin; J L Hungerford
Journal:  Br J Ophthalmol       Date:  1999-05       Impact factor: 4.638

7.  Uveal melanoma-associated survival in Scotland.

Authors:  Aaron Jamison; Lesley A Bhatti; Manvi M Sobti; Vikas Chadha; Paul Cauchi; Ewan G Kemp
Journal:  Eye (Lond)       Date:  2019-10-25       Impact factor: 3.775

8.  Risk factors for metastatic uveal melanoma after trans-scleral local resection.

Authors:  B E Damato; J Paul; W S Foulds
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

9.  Histopathology studies in human malignant melanomas of the choroid after unsuccessful treatment with 106Ru/106Rh ophthalmic applicators.

Authors:  H Klaus; P K Lommatzsch; U Fuchs
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

Review 10.  Tumor Characteristics, Genetics, Management, and the Risk of Metastasis in Uveal Melanoma.

Authors:  Erin E Nichols; Ann Richmond; Anthony B Daniels
Journal:  Semin Ophthalmol       Date:  2016-04-29       Impact factor: 1.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.